Development of a core set of outcome measures to be applied toward breast cancer-related lymphedema core outcome domains
Breast Cancer Research and Treatment · 2024
DOI: 10.1007/s10549-024-07298-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von David Doubblestein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Therapy, A.T. Still University, Mesa, AZ, USA. daviddoubblestein@atsu.edu. Hauptthemen laut MEDLINE: Breast Cancer Lymphedema, Outcome Assessment, Health Care, Cancer Survivors, Delphi Technique. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: A.T. Still University, Mesa.
Abstract (Originalsprache)
Purpose
For breast cancer survivors (BCS) living with breast cancer-related lymphedema (BCRL), what outcome measures (OMs) are recommended to be used to measure standardized outcome domains to fully assess the burden of the disease and efficacy of interventions? An integral component of a standardized core outcome set (COS) are the OMs used to measure the COS.
Methods
A supplemental online survey was linked to a Delphi study investigating a COS for BCRL. OMs were limited to a maximum of 10 options for each outcome domain (OD). There were 14 ODs corresponding to the International Classification of Functioning, Disability, and Health (ICF) framework and respondents rated the OMs with a Likert level of recommendation. The feasibility of the listed OMs was also investigated for most outpatient, inpatient, and research settings.
Results
This study identified 27 standardized OMs with a few ODs having 2–3 highly recommended OMs for proper measurement. A few of the recommended OMs have limitations with reliability due to being semi-quantitative measures requiring the interpretation of the rater.
Conclusion
Narrowing the choices of OMs to 27 highly recommended by BCRL experts may reduce selective reporting, inconsistency in clinical use, and variability of reporting across interdisciplinary healthcare fields which manage or research BCRL. There is a need for valid, reliable, and feasible OMs that measure tissue consistency. Measures of upper extremity activity and motor control need further research in the BCS with BCRL population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physical Therapy, A.T. Still University, Mesa, AZ, USA. daviddoubblestein@atsu.edu.
- Department of Rehabilitation Medicine, University of Minnesota, Minneapolis, MN, USA.
- Sinclair School of Nursing, University of Missouri, Columbia, MO, USA.
- Occupational Therapy Assistant Program, Huntington University, Huntington, IN, USA.
- Parkridge Medical Center - Wound Care/Lymphedema Clinic, Parkridge Medical Center, Chattanooga, TN, USA.
- Division of Surgery, Department of Plastic Surgery, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Förderung
- A.T. Still University, Mesa
Zitieren
APA
Doubblestein, D., Koehler, L., Anderson, E., Scheiman, N., Stewart, P., Schaverien, M., & Armer, J. (2024). Development of a core set of outcome measures to be applied toward breast cancer-related lymphedema core outcome domains. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07298-7
Vancouver
Doubblestein D, Koehler L, Anderson E, Scheiman N, Stewart P, Schaverien M, et al. Development of a core set of outcome measures to be applied toward breast cancer-related lymphedema core outcome domains. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07298-7
BibTeX
@article{Doubblestein2024,
author = {Doubblestein, David and Koehler, Linda and Anderson, Elizabeth and Scheiman, Nicole and Stewart, Paula and Schaverien, Mark and Armer, Jane},
title = {Development of a core set of outcome measures to be applied toward breast cancer-related lymphedema core outcome domains},
journal = {Breast Cancer Research and Treatment},
year = {2024},
doi = {10.1007/s10549-024-07298-7}
}
EUVIMED